“Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti-fibrotic interventions is an important target for research and therapy in cardiology.
It has been suggested that compounds with anti-inflammatory and antioxidant properties (such as cannabinoids) may represent interesting therapeutic alternatives, due to their ability to influence pro-fibrotic signalling and inhibit pathological extracellular matrix deposition in the heart.
This review describes the more important signalling pathways involved in cardiac fibrosis and some new concepts regarding the utility of cannabinoids and modulation of the endocannabinoid system (ESC) as therapeutic interventions against cardiac fibrosis.
The studies presented in this review suggest that specific cannabinoid type 2 receptor activation and peripheral cannabinoid Type 1 receptor blockade appear particularly promising.
The potential for the cardioprotective anti-fibrotic effects of cannabinoids and ECS modulators appears to lie in their high antioxidant and anti-inflammatory efficacy, which limits the progression of fibrotic lesions and restores normal regulation of molecular signalling pathways.”
https://pubmed.ncbi.nlm.nih.gov/41662725
“The studies presented in this review confirm that cannabinoids (especially CBD and β-CP) and modulating the activity of the ECS may be useful therapeutically in states of pathological cardiac remodelling and fibrosis; specific activation of CB2 receptors and peripheral blockade of CB1 receptors seems particularly promising as an adjuvant therapies.
In addition to their anti-fibrotic effects in the course of various diseases, it appears that cannabinoids may improve cardiac regeneration after MI and reduce infarct size, which, given the minimal ability of cardiomyocytes to proliferate after ischaemic damage, may represent a promising direction for modern regenerative medicine to restore the structural and functional integrity of the myocardium.
The greatest potential for the cardioprotective anti-fibrotic effect of cannabinoids and ECS modulators appears to lie in their high antioxidant and anti-inflammatory efficacy, which limits the progression of fibrotic changes and restores the normal regulation of molecular signalling pathways.”
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70347